Biovaxpharma-Inhalosomes - Development of a nonionic surfactant vesicle platform formulation for drug encapsulation and pulmonary delivery

Biovaxpharma-Inhalosomes - 开发用于药物封装和肺部输送的非离子表面活性剂囊泡平台配方

• 批准号: 720199
• 金额: $ 25.06万
• 依托单位: INHALOSOME-C LTD
• 依托单位国家: 英国
• 项目类别: GRD Development of Prototype
• 财政年份: 2013
• 资助国家: 英国
• 起止时间: 2013 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=720199
• 关键词: Biovaxpharma; Inhalosomes; Development; nonionic; surfactant

Inhalosomes are lipid nanoparticles designed to tackle the unmet need for effective treatment of serious pulmonary diseases, such as in cancer, infection and autoimmunity. Current systemic treatments are only partially effective as they are a blanket approach where low levels of drug reach the lung. Inhalosome vesicles will be develop as a platform drug encapsulating technology that can be aerosolized for lung delivery to provide significant improvements in therapy. The initial intention is to demonstrate the feasibility of Inhalosomes for the treatment of lung cancer, particularly non-small cell lung cancer (NSCLC). With this project, the Inhalosome prototype will be manufactured to cGMP and the stability of the formulation tested Using the manufactured Inhalosome preparation, subsequent studies will evaluate the Inhalosome-cisplatin for toxicology and in Phase I and II studies to demonstrate safety and efficacy in man for treating NSCLC. Expectations are that the Cisplatin-Inhalosome combination will significantly increase the effectiveness of NSCLC chemotherapy treatment, increasing the survival rate and extend life expectancy and will improve the patient experience.

吸入的是脂质纳米颗粒，旨在应对有效治疗严重肺部疾病（例如癌症，感染和自身免疫性）的未满足需求。当前的全身治疗仅是部分有效的，因为它们是一种覆盖量的方法，其中低水平的药物到达肺部。吸入囊泡将作为一种平台药物封装技术开发，可以将其雾化以肺部递送，从而在治疗方面得到显着改善。最初的目的是证明吸入肺癌治疗的可行性，尤其是非小细胞肺癌（NSCLC）。借助该项目，将不使用cGMP制造不吸毒原型，并使用制造的非腔体制备进行测试的制剂的稳定性，随后的研究将评估毒理学以及I型和II期中的毒素和II研究中的毒素 - 静脉曲张，以证明对男子治疗NSCLC的安全性和有效性。预期的是，顺铂吸入体的组合将显着提高NSCLC化学疗法治疗的有效性，提高生存率并延长预期寿命，并可以改善患者的体验。